Randomized phase III study comparing erlotinib plus bevacizumab to erlotinib alone in patients with previously untreated non-small cell lung cancer harboring EGFR mutation (NEJ026)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Oct 2016 Trial design was presented at the 41st European Society for Medical Oncology Congress
- 05 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 20 May 2015 Status changed from not yet recruiting to recruiting as reported by UMIN record.